High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.

作者：Mark W. Brunvand, Jack W. Singer, E. Soll, Charles H. Weaver, Scott D. Rowley, F R Appelbaum, Kathy Lilleby, R. A. Clift, Ted Alan Gooley, Oliver W. Press, A Fefer, Rainer F Storb, Jean E. Sanders, Patrick Martin, Thomas R. Chauncey, Richard Thomas Maziarz, N. Zuckerman, Paul G. Montgomery, Ronald V. Dorn, PAUL L. WEIDEN, Taner Demirer, Leona Holmberg, K Schiffman, Peter A. McSweeney, C. Dean Buckner · 发表于：PubMed · 年份：1996 · 被引用次数：646 · 研究领域：Effects of Radiation Exposure、Carcinogens and Genotoxicity Assessment、Childhood Cancer Survivors' Quality of Life

Consecutive patients with non-Hodgkin's lymphoma (NHL, n = 133) or Hodgkin's disease (HD, n = 20) were treated with 12.0 Gy of fractionated total body irradiation, etoposide 60 mg/kg, and CY 100 mg/kg followed by infusion of autologous hematopoietic stem cells. Seventy-nine patients received purged (n = 62) or unpurged BM (n = 17), and 74 received unpurged PBSCs alone (n = 56) or with BM (n = 18). The median day for achieving a sustained granulocyte count of 0.5 x 10(9)/I was 14 range (7-66) for BM recipients and 10 (7-30) for PBSC +/- BM recipients (P = 0.03). A platelet count of 20 x 10(9)/I was achieved at a median of day 24 (6-145) in BM recipients and day 11 (range, 7-56) in PBSC +/- BM recipients (P = 0.007). The median number of platelet units transfused was 86 (0-1432) for BM recipients and 30 (6-786) for PBSC +/- BM recipients (P = 0.001). The median number of hospital days was 36 (10-88) for BM recipients and 27 (14-76) for PBSC +/- BM recipients (P = 0.0001). The unadjusted Kaplan-Meier (KM) estimates of survival, event-free survival (EFS) and relapse at 2 years were 0.57, 0.45 and 0.43 for patients receiving BM and 0.55, 0.36 and 0.59 for patients receiving PBSC +/- BM. After adjusting for confounding variables, the estimated relative risk (RR) of death from any cause was 0.92 (P = 0.75), of relapse was 1.25 (P = 0.39), of non-relapse mortality was 0.71 (P = 0.42) and of mortality and/or relapse was 1.17 (P = 0.48) for patients receiving PBSC +/- BM as compared to...